Canoo reports quarterly losses of $1.13 per share, missing the analyst consensus estimate of losses of 97 cents by 16.49%. The company reported zero in quarterly sales, in-line with estimates.
Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non-surgical RRP treatment.
Edwards Lifesciences faces EU antitrust complaint from Meril over patent disputes, intensifying regulatory scrutiny. Recent actions aim to ensure fair competition, affordability, as Meril alleges patent abuses and obstruction to innovation.